EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance

Elisabetta Grillo, Chiara Romani, Victoria M Ettorre, Alessandro D Santin, Stefania Mitola

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025-09 · 1880 (4) · 189374

DOI: 10.1016/j.bbcan.2025.189374 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025-09. Verfasst von Elisabetta Grillo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, 25123 Brescia, Italy. Electronic address: elisabetta.grillo…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Vascular Endothelial Growth Factor Receptor-2, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione Umberto Veronesi, Associazione Italiana per la Ricerca sul Cancro, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The vascular endothelial growth factor receptor 2 (VEGFR2) is a tyrosine kinase receptor regulating a variety of biological processes, including embryonic development, angiogenesis, tissue homeostasis and cancer. VEGFR2 is activated by canonical VEGFs and non-canonical ligands, triggering intracellular signaling cascades that mediate its biological activity. Preclinical studies show that VEGFR2 plays a complex yet pivotal role in the progression of ovarian cancer (OC), a deadly disease with a global burden of more than 320,000 women in 2022. Several inhibitors of the VEGF/VEGFR2 axis have been developed and are currently approved or included in clinical trials/preclinical studies for the therapy of different subtypes of OC. Originally developed as anti-angiogenics, anti-VEGF/VEGFR2 drugs are now well-known to also affect tumor cells, immune cells and cancer-associated fibroblasts (CAFs), also in OC. In this review we address the specific role of the VEGF/VEGFR2 axis in OC cells, and, from this perspective, we discuss the therapeutic significance of VEGFR2 targeting. Dissection of the molecular landscape modulated by the VEGF/VEGFR2 system in tumor cells in addition to stromal ones will facilitate ongoing translational efforts directed toward OC therapy. SIGNIFICANCE STATEMENT: Anti-angiogenics blocking the VEGF/VEGFR2 axis are widely used to treat ovarian cancer, although resistance and poor response occur. Recent advances reveal that anti-VEGF/VEGFR2 drugs act on multiple compartments, including ovarian cancer cells. This review discusses the functional and pharmacological significance of the VEGF/VEGFR2 axis in ovarian cancer cells highlighting insights from preclinical and clinical studies. A deeper understanding of this pathway is essential for a safe/efficacious usage of anti-angiogenics targeting the VEGFR2 pathway in ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor AHumansFemaleSignal TransductionAnimalsAngiogenesis InhibitorsNeovascularization, PathologicMolecular Targeted Therapy

Stichwörter der Autor:innen

HGSOCOvarian cancerTKiVEGFVEGFR2

Substanzen

Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor AKDR protein, humanAngiogenesis InhibitorsVEGFA protein, human

Autor:innen und Institutionen

  • Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, 25123 Brescia, Italy. Electronic address: elisabetta.grillo@unibs.it.
  • Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
  • Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, CT 06520, United States of America.
  • Department of Molecular and Translational Medicine, University of Brescia, Via Branze 39, 25123 Brescia, Italy. Electronic address: stefania.mitola@unibs.it.

Förderung

  • Fondazione Umberto Veronesi
  • Associazione Italiana per la Ricerca sul Cancro
  • European Commission
  • Università degli Studi di Brescia
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Zitieren

APA

Grillo, E., Romani, C., Ettorre, V. M., Santin, A. D., & Mitola, S. (2025). The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1880(4), 189374. https://doi.org/10.1016/j.bbcan.2025.189374

Vancouver

Grillo E, Romani C, Ettorre VM, Santin AD, Mitola S. The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(4):189374. doi:10.1016/j.bbcan.2025.189374

BibTeX
@article{Grillo2025,
  author = {Grillo, Elisabetta and Romani, Chiara and Ettorre, Victoria M and Santin, Alessandro D and Mitola, Stefania},
  title = {The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2025},
  volume = {1880},
  number = {4},
  pages = {189374},
  doi = {10.1016/j.bbcan.2025.189374}
}
Kostenlos starten →